It refers to a pharmacodynamic synthesis, including: (a) a quinase PI3K inhibitor, such as compound 2-amine-8-ethyl-4-methyl-6 - (1h-pirazol-5-il) pyridine [2, 3-d] pyridine-7 (8h) - ona, with a content of 30, 50, 70 or 90mg； (b) a MEK inhibitor, such as compound n - ((s) - 2, 3-dihydropropyl-3 - (2-fluoro-4-iodo-phenyl) isonicotine, 15, 30, 60 or 90 mg. He also mentioned a package that included pharmaceutical ingredients and appropriate packaging. This composition is very useful for the treatment of cancerSE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA QUINASA PI3K TAL COMO EL COMPUESTO 2-AMINO-8-ETIL-4-METIL-6-(1H-PIRAZOL-5-IL)PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONA EN UNA CANTIDAD DE 30, 50, 70 O 90MG； Y B) UN INHIBIDOR DE MEK TAL COMO EL COMPUESTO N-((S)-2,3-DIHIDROXIPROPIL)-3-(2-FLUORO-4-YODO-FENILAMINO)ISONICOTINAMIDA EN UNA CANTIDAD DE 15, 30, 60 O 90MG. TAMBIEN SE REFIERE A UN KIT QUE COMPRENDE LA COMPOSICION FARMACEUTICA Y UN ENVASE ADECUADO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL CANCER
